HistoSonics is the creator of an innovative, non-intrusive sonic beam therapy platform designed to annihilate targeted tissues at a sub-cellular level by liquefying them. The company's platform provides custom, tissue-specific treatments with unmatched accuracy and control, devoid of the unwanted side effects commonly associated with current surgical and interventional methods. This allows physicians to consistently monitor the treatment and its impact in real time.

Investors Include:

Grand Rapids Business Journal, Gary Comer, HealthQuest Capital, Alpha Wave Global, Varian Medical Systems, Johnson & Johnson Innovation - JJDC, Frederic Moll, Amzak Health, Venture Investors, Fletcher Spaght Ventures, Hatteras Venture Partners, Trout Creek Ventures, State of Wisconsin Investment Board, Early Stage Partners, Lumira Ventures, Grand Angels, Yonjin Venture, Innovation Partnerships, TGap Ventures, Samuel Zell & Robert H Lurie, MINTS (Michigan Investment in New Technology Startups), Daniel Weide, Michigan Capital Network Ventures, Northern Michigan Angels.

Own HistoSonics stock or options?

Get an instant valuation

Completely free
100% confidential & secure
Takes less than a minute

What company do you own stock or options in?

How many shares or options do you own?

100% private & secure

Our available services for this company

Lifetime IncomeCharitable Remainder Trust

Tax SavingsDonor Advised Fund